Last reviewed 2026-04-20 · How we verify

Gludiase (GLYBUZOLE)

Phase 2 active Small molecule

Gludiase (generic name: GLYBUZOLE) is a glybuzole drug. It is currently in Phase 2 development.

Gludiase works by interacting with a specific biological target to produce a therapeutic effect.

Gludiase, also known as Glybuzole, is a small molecule drug in the glybuzole class. Its mechanism of action and target are currently unknown. It is unclear if Gludiase has been approved by the FDA or if it is commercially available. Further research is needed to determine its safety profile and potential indications.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	GLYBUZOLE
Drug class	glybuzole
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like a city with many different buildings. Gludiase is like a key that unlocks a specific building, allowing it to function properly and helping to treat a particular condition.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Gludiase CI brief — competitive landscape report
Gludiase updates RSS · CI watch RSS

Frequently asked questions about Gludiase

What is Gludiase?

Gludiase (GLYBUZOLE) is a glybuzole drug.

How does Gludiase work?

Gludiase works by interacting with a specific biological target to produce a therapeutic effect.

What is the generic name of Gludiase?

GLYBUZOLE is the generic (nonproprietary) name of Gludiase.

What drug class is Gludiase in?

Gludiase belongs to the glybuzole class. See all glybuzole drugs at /class/glybuzole.

What development phase is Gludiase in?

Gludiase is in Phase 2.

Drug class: All glybuzole drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing